Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) Asset Utilization Ratio: 2021-2025

Historic Asset Utilization Ratio for Allogene Therapeutics (ALLO) over the last 4 years, with Sep 2025 value amounting to -0.00.

  • Allogene Therapeutics' Asset Utilization Ratio fell 3170.12% to -0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was -0.00, marking a year-over-year decrease of 3170.12%. This contributed to the annual value of 0.00 for FY2024, which is 71.54% down from last year.
  • Allogene Therapeutics' Asset Utilization Ratio amounted to -0.00 in Q3 2025, which was down 51.28% from -0.00 recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Asset Utilization Ratio ranged from a high of 0.11 in Q4 2021 and a low of -0.00 during Q3 2025.
  • In the last 3 years, Allogene Therapeutics' Asset Utilization Ratio had a median value of 0.00 in 2023 and averaged -0.00.
  • Data for Allogene Therapeutics' Asset Utilization Ratio shows a maximum YoY crashed of 3,170.12% (in 2025) over the last 5 years.
  • Over the past 5 years, Allogene Therapeutics' Asset Utilization Ratio (Quarterly) stood at 0.11 in 2021, then crashed by 99.83% to 0.00 in 2022, then declined by 22.95% to 0.00 in 2023, then plummeted by 273.15% to -0.00 in 2024, then slumped by 3,170.12% to -0.00 in 2025.
  • Its Asset Utilization Ratio was -0.00 in Q3 2025, compared to -0.00 in Q2 2025 and -0.00 in Q1 2025.